Efficient Strategies for Microglia Replacement in the Central Nervous System (vol 32, 108041-14.E1, 2020)

Zhen Xu,Yanxia Rao,Yubin Huang,Tian Zhou,Rui Feng,Shanshan Xiong,Ti-Fei Yuan,Shan Qin,Yijie Lu,Xin Zhou,Xiaoyu Li,Bo Qin,Ying Mao,Bo Peng
DOI: https://doi.org/10.1016/j.celrep.2020.108443
IF: 8.8
2020-01-01
Cell Reports
Abstract:(Cell Reports 32, 108041-1–108041-14.e1–e6; August 11, 2020) In the originally published version of this article, the calculation to estimate the percentage of CCR2+ cell-derived mrPB cells was incorrectly changed by the production team. This calculation is corrected as “the estimated proportion of CCR2-positive cell-derived mrPB cells among all mrPB cells is 71.20% (57.49% ÷ 0.8074)” and now appears with the paper online. The production team regrets this error. Additionally, the bone marrow cell (BMC) number transplanted (by either tBMT, mrBMT, or mrMT) was incorrectly listed by the authors. The corrected number, 1 × 107 BMCs were transplanted, now appears with the paper online. The authors regret this error. Efficient Strategies for Microglia Replacement in the Central Nervous SystemXu et al.Cell ReportsAugust 11, 2020In BriefThe bottleneck for microglia-based gene therapy is the lack of tools for genetic manipulation of microglia and/or their allotransplantation. In this study, Xu et al. develop three strategies achieving efficient microglia replacement at the CNS-wide scale or specific brain regions of interest. Each approach has its own advantages and application scenarios. Full-Text PDF Open Access
What problem does this paper attempt to address?